


REMARKS

Favorable consideration of the application is requested in view of the amendments to the claims and the remarks presented herein.

The claims now in the application are claims 28 to 31 and 33 to 49, all other claims having been cancelled.


Applicants are submitting herewith three references which are pertinent to the prosecution of the present application. These include European patent application No. 0 561 639; EPO 0 736 541 and British patent application No. 2 251 955. Also submitted herewith is PTO Form-1449.

British application. No.2 241 955 has compounds of the formula



wherein there is a substituent $-\text{CH}_2\text{COH}_2$ in the alpha position to the hydroxyl group which corresponds to substituent T of Applicants' formulae. R_2 is always hydrogen whereas in Applicants' position, the corresponding substituent is a hydroxyl.


EP 0 736 541 discloses compounds of the formula



I

wherein R^{X1}, R^{X2}, R^{Y1} and R^{Y2} are hydroxyl or hydrogen, R' is hydrogen, methyl or -NH₂C(O)CH₂-. R'' and '' are independently hydrogen or methyl.

EPO No. 0 561 639 discloses compounds of the formula



wherein R' is hydrogen or methyl or $\text{NH}_2\text{C}(\text{O})\text{CH}_2$ - which substituent corresponds to Applicants' T and R is either hydrogen or hydroxyl.

Claim 28 distinguishes from the references discussed above since in the British patent application No. 2 241 955, R_2 is always hydrogen wherein Applicants have it in the same position a hydroxyl. With respect to the '541 reference, claim 28 has W and T as hydrogen. With respect to the '639 reference, it should be noted that W and T are directed to hydrogen. Claim 30 is dependent upon claim 28 and is distinguished in the same fashion.


Claim 29 is now dependent upon claim 31 and the second and third compounds of which are drawn to examples 14 and 15. The first compound is supported in lines 44 to 52 of column 8 of the issued parent patent. With respect to claim 31, this is directed to compounds wherein there is an oxo group at the top of the cyclohexapeptide which is not the case of the references and therefore, claim 31 is distinct in this part. Claim 32 has been cancelled.

Claim 33 is directed to the compounds of formula IV and distinguishes from the British patent in the fact that the R₂ substituent in the reference is always hydrogen while Applicants' compounds have a hydroxyl at this point. With respect to the '541 reference, Applicants' compounds distinguish therefrom wherein W and T are both hydrogen. With respect to the '639 reference, R is dihydroxy or dideoxy and Applicants' compounds have hydrogen for W. Therefore, none of the references anticipate or render obvious Applicants' compounds.

The present amendment also corrects a couple of typographical errors in the original claims and presents new dependent claims 44 to 49.

Therefore, favorable consideration of the application is requested.

Respectfully submitted,
Muserlian, Lucas and Mercanti



Charles A. Muserlian, 19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures